These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 28352061)
1. Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer? Choi YW; Choi JH Korean J Intern Med; 2017 May; 32(3):422-428. PubMed ID: 28352061 [TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356 [TBL] [Abstract][Full Text] [Related]
3. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500 [TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039 [TBL] [Abstract][Full Text] [Related]
5. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243 [TBL] [Abstract][Full Text] [Related]
7. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810 [TBL] [Abstract][Full Text] [Related]
9. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963 [TBL] [Abstract][Full Text] [Related]
10. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Tan CS; Cho BC; Soo RA Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828 [TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755 [TBL] [Abstract][Full Text] [Related]
13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
14. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. Lopes GL; Vattimo EF; Castro Junior Gd J Bras Pneumol; 2015; 41(4):365-75. PubMed ID: 26398757 [TBL] [Abstract][Full Text] [Related]
15. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111 [TBL] [Abstract][Full Text] [Related]
17. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]
18. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Liao BC; Lin CC; Yang JC Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025 [TBL] [Abstract][Full Text] [Related]
19. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients. Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948 [TBL] [Abstract][Full Text] [Related]
20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]